WVE-006

RNA / oligonucleotide

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Alpha-1 Antitrypsin Deficiency
Phase 1 (1)
Alpha-1 Antitrypsin Deficiency

Competitive landscape

This drug's own stage for Alpha-1 Antitrypsin Deficiency: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
WVE-006: this drugPhase 1/2RNA / oligonucleotideSERPINA1 Z-allele mRNA (ADAR-mediated editing)not yet gradedNo reviewed efficacy summary in this indication
FazirsiranPhase 3RNA / oligonucleotideSERPINA1not yet gradedNo reviewed efficacy summary in this indication
AlvelestatPhase 2Small moleculeNeutrophil elastasePartial signal
NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively).
BEAM-302Phase 1/2Gene therapy / editingSERPINA1 PiZ mutation (E342K)not yet gradedNo reviewed efficacy summary in this indication
TSRA-196Phase 1/2Gene therapy / editingSERPINA1not yet gradedNo reviewed efficacy summary in this indication
KB408Phase 1Gene therapy / editingSERPINA1 (alpha-1 antitrypsin; gene replacement)not yet gradedNo reviewed efficacy summary in this indication
Efdoralprin Alfa
—(overall)
Protein / enzyme therapeuticAlpha-1 antitrypsin (AAT)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow WVE-006 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Phase 1/2Alpha-1 Antitrypsin DeficiencyRecruiting
Est. primary completion 2027-09 · NCT06405633 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 May 2026Topline resultRestorAATion-2 (NCT06405633) multidose update: total AAT 13.6 uM at 400 mg, MZ-like levels with biweekly and monthly dosing